Luspatercept-aamt

Details of the Drug

Generic Name:: Luspatercept-aamt
Drug Type:: Erythroid maturation agent
How the Drug is Given:: Injection, for subcutaneous use
Names:: Reblozyl®; Luspatercept-aamt

Indications and Usage

Luspatercept-aamt is FDA approved for the treatment of:

Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.
Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

Limitations of Use: Reblozyl is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Side effects needing medical attention

The most common adverse reactions were fatigue, headache, musculoskeletal pain, pain in a joint (arthralgia), dizziness/vertigo, nausea, diarrhea, cough, abdominal pain, difficulty breathing (dyspnea), and hypersensitivity.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.